Filling and Closing Machine Features Integrated Capping Station - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Filling and Closing Machine Features Integrated Capping Station



The FXS Combi, a filling and closing machine from Bosch Packaging Technology, features an integrated capping station for vials and cartridges. This machine can be integrated into line concepts and is suited for low- and medium-output rates.

The FXS Combi operates with a combi filling station with up to six dosing heads. This makes the machine suitable for all common filling technologies, such as peristaltic or rotary slide valve piston pumps as well as the single-use filling technology PreVAS. A combination with different barrier systems is also possible because the FXS Combi is suited for both restricted access barrier systems and isolators. By combining this filling and closing machine with the upstream ATO tub opener and ABO bag opener from Bosch, it can be integrated into fully automated line concepts.

This device is also suited for processing vials for lyophilization, which helps expand the life span of pharmaceuticals. According to the company, filling on a checkweigher during the start-up and run-empty process makes almost 100% of the pharmaceutical liquids usable for filling.

The filling and closing machine was introduced at Interpack 2014.

Source: Bosch Packaging Technology

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here